Evidence map›Paper›PMID 29285110›Full record

ArticleExperimental and therapeutic medicine2017

Large scale

Huiying Yu, Wei Chen, Changling Li, Di Lin, Junde Liu, Zien Yang, Jingang Yang, Yinghui Sun, Dongchu Ma

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Huiying YuDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Wei ChenDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Changling LiDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Di LinDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Junde LiuDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Zien YangDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Jingang YangDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Yinghui SunDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Dongchu MaDepartment of Experimental Medicine, Northern Hospital, Shenyang, Liaoning 110016, P.R. China.
Shenyang 242 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-based adoptive immunotherapy for the treatment of various cancer types has attracted the attention of scientists. However, due to the absence of unitary standard protocols to produce large quantities of clinical-grade effector cells, it remains challenging to translate the experimental findings into clinical applications. The present study used methods complying with good manufacturing practice to induce effector cells from human peripheral blood mononuclear cells (PBMCs) of healthy donors by interleukin-2 and anti-Her-2 antibody with or without anti-CD3 antibodies (OKT3). The results indicated that the addition of OKT3 resulted in a greater expansion of the total cells and CD8

Indexed as

adoptive immunotherapyeffector cellsHer-2

Identifiers

PMID29285110
PMCPMC5740814
OpenAlexW2757736840

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.